What is TuHURA Biosciences, Inc.'s stock issuance proceeds?

TuHURA Biosciences, Inc. (HURA) reported stock issuance proceeds of $7.5M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

TuHURA Biosciences, Inc. HURA Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

CTO

Citius Oncology, Inc.CTOR

$15.13M—

Inhibrx Biosciences, Inc.INBX

$471K—

Corvus PharmaceuticalsCRVS

$189.41M+67,788%

ImmunityBio, Inc.IBRX

$971K+341%

Avalo TherapeuticsAVTX

$2.18M—

Janux TherapeuticsJANX

$3.55M+293%

Other financials

Income statement

See full

Revenue-—

Net income-$7.5M-13.1%

EPS (diluted)-$0.13+13.3%

Balance sheet

See full

Cash & equivalents$6.3M+1.3%

Total debt$456.9K+178%

Total equity$23.2M+135%

Total assets$29.7M+103%

Cash flow

See full

Operating cash flow-$4.4M+6.9%

CapEx$48.8K+14.5%

Free cash flow-$4.5M+6.7%

Valuation

See full

Market cap$155.39M+45.8%

Enterprise value$149.54M+52.3%

Returns & leverage

See full

Return on equity-187.2%—

Debt / equity0×0.0×

Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s stock issuance proceeds?: TuHURA Biosciences, Inc. (HURA) reported stock issuance proceeds of $7.5M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.